New study tracks Dupilumab's Long-Term impact on chronic itch condition
NCT ID NCT07276425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 40 adults with moderate-to-severe prurigo nodularis who are starting dupilumab (Dupixent). Researchers will track how well the drug controls itching and skin lesions over time, and also study changes in immune cells and proteins in the skin and blood. The goal is to understand how dupilumab works and to improve personalized treatment for this chronic skin condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dupilumab (Dupixent)
- What this could lead to
- If successful, this could confirm dupilumab as a reliable long-term treatment for moderate-to-severe prurigo nodularis and help personalize therapy.
- What could go wrong
- This is a small, early-phase study with only 40 participants, so results may not apply to everyone. Dupilumab can cause side effects like injection reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRURIGO NODULARIS (PN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Medical Center Utrecht
RECRUITINGUtrecht, Utrecht, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.